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Cardiovascular diseases are 
responsible for one-third of global 
deaths and during recent years 
cardiovascular medicines have been 
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blood pressure and serum lipids and 
was based on Kuopio 75+ study and 
GeMS study. 
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ABSTRACT 
 
Cardiovascular diseases are responsible for one-third of global deaths and 
during recent years cardiovascular medicines have been the most 
commonly used medication among elderly persons. Today there are no 
age-specific guidelines on how to treat cardiovascular diseases in the 
elderly population. The target levels of blood pressure and blood lipids as 
well as the values at which treatments is started have become lower and 
lower over the years also among elderly persons. The present series of 
studies were designated to examine the use of cardiovascular medicines use 
with a special emphasis on blood pressure and serum lipids. According to 
the study, the use of cardiovascular medicines was common among elderly 
persons and the proportion of users increases with age and over time. In 
addition, the trend in current statin use seems to be moving towards more 
extensive use. The result shows that low serum total cholesterol level was 
associated with an increased risk of all-cause mortality among elderly who 
did not use serum lipid modifying medication. In studies concentrating on 
blood pressures, the orthostatic hypotension and drops in blood pressure 
seem to be more common than has previously been reported.  The more 
medicines are in regular use, the more common is orthostatic hypotension. 
Since the increased and concomitant use of several cardiovascular 
medicines among elderly persons makes them sensitive to partly unknown 
adverse effects, it is important to assess the patient’s physical function and 
outcomes of treatment. As well the medication monitoring focused on 
elderly patients and cardiovascular medication might optimise treatment 
and improve the quality of care for a large proportion of elderly persons.  
 
National Library of Medicine Classification: WB330, WG120, WT166, Q95, QV150. 
Medical Subject Headings (MeSH): Cardiovascular Diseases/drug therapy; Blood 
Pressure; Lipids/blood; Cardiovascular Agents/therapeutic use; Anticholesteremic 
Agents/therapeutic use; Cholesterol; Choresterol, HDL; Cholesterol, LDL; 
Hypotension, Orthostatic;  Mortality; Aged, 80 and over 
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TIIVISTELMÄ 
 
Sydänsairaudet ovat osana kolmasosassa kuolemia ja sydänsairauksien 
lääkkeet ovat olleet vuosia eniten käytetty lääkeryhmä ikääntyneillä. Tällä 
hetkellä ei ole käytössä ikäspesifisiä hoitosuosituksia sydänsairauksien 
hoitoon, vaan hoito pohjautuu koko väestön kattaviin hoitosuosituksiin. 
Tutkimuksessa selvitettiin suomalaisten iäkkäiden (≥ 75 vuotta) sydän- ja 
verenpainelääkkeiden käyttöä ja kulutusta tutkimusvuosina 1998–2006. 
Tutkimuksessa keskityttiin erityisesti kolesteroli- ja verenpainelääkityksen 
erityispiirteisiin iäkkäillä. Työ perustuu neljään osatyöhön, joissa on 
käytetty Kuopio 75+ sekä Hyvän Hoidon Strategia (HHS) tutkimuksista 
saatuja terveys- ja lääkedatoja. Tutkimuksen mukaan sydänsairauksien 
lääkkeiden käyttö oli yleistä ja käyttäjien osuus kasvoi ikääntymisen ja ajan 
myötä. Vuonna 2003 jopa 87 %:lla tutkittavista oli yksi tai useampi 
sydänsairauksien lääke. Erityisesti kohonneen kolesterolin hoitoon 
käytettävien statiinien käyttö lisääntyi tutkimusaikana. Tulosten mukaan 
matala kolesteroli oli yhteydessä lisääntyneeseen kuolleisuuteen 
tutkittavilla, jotka eivät käyttäneet kolesterolilääkitystä. Tutkittaessa 
verenpaineita saatiin selville, että ortostaattinen hypotonia ja verenpaineen 
lasku näyttää olevan yleisempää kuin aiemmin on raportoitu. Mitä 
enemmän tutkittavilla oli säännöllisiä lääkkeitä käytössä, sitä yleisempää 
oli ortostaattinen hypotonia. Koska lisääntynyt ja usein yhtäaikainen 
lääkkeiden käyttö iäkkäillä saattaa altistaa tuntemattomille 
haittavaikutuksille, on tärkeää arvioida säännöllisesti potilaan fyysinen 
kunto ja hoidon tulokset. Myös lääkityksen säännöllinen arviointi iäkkäillä 
sydänsairailla auttanee parantamaan hoidon laatua ja parantaa iäkkäiden 
elämänlaatua. 
 
Yleinen suomalainen asiasanasto: HDL-kolesteroli; ikääntyminen; ikääntyneet; 
LDL-kolesteroli; lääkehoito; lääkkeet - - käyttö; kolesteroli; verenpaine; lipidit - - 
veri; sydän- ja verisuonitaudit 
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1 Introduction 
Cardiovascular diseases are responsible for one-third of 
global deaths and they are a leading and increasing 
contributor to the global disease burden (WHO 2002, 
Kesteloot et al. 2002). The prevalence of cardiovascular 
diseases increases with advancing age, leading to 
concomitant use of several medications. 
In addition, the proportion of elderly persons is increasing 
in Finland and other western countries and, in general, 
elderly populations are often treated more actively than 
before. Many studies have reported an overall increase in the 
use of medicines among the elderly (Lernfelt et al. 2003). In 
Finland, the amount of drugs used has increased among both 
men and women, especially among persons aged 85 years 
and over (Linjakumpu et al. 2002b, Jyrkkä et al. 2006). During 
recent years cardiovascular medicines have been the most 
commonly used medications among elderly persons (Barat et 
al. 2000, Linjakumpu et al. 2002b, Kaufman et al. 2002).  
Today there are no age-specific guidelines on how to treat 
cardiovascular diseases in the elderly population, but the 
goals are mainly the same as in the middle-aged population 
(Käypä hoito: Kohonnut verenpaine 2009, Käypä hoito: 
Dyslipidemiat 2009). The target levels of blood pressure and 
blood lipids as well as the values at which treatments are 
started have become lower and lower over the years also 
among elderly persons (Salomaa et al. 1994, Chobanian et al. 
2003, Graham et al. 2007). For middle-aged patients with 
vascular disease, high serum total cholesterol as well as high 
blood pressure are associated with greater all-cause and 
cardiovascular mortality, and the benefits of treatments are 
well documented (Stamler et al. 1999, Stamler et al. 2000). 
However, the number of elderly participants in trials has 
been rather limited. In addition, some observational studies 
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of persons aged 65 years or older suggest that traditional risk 
factors like elevated cholesterol and blood pressure might be 
inversely associated with total mortality (Mattila et al. 1988, 
Schatz et al. 2001, Rastas et al. 2006). 
Increased and concomitant use of several cardiovascular 
medicines among elderly persons makes them sensitive to 
partly unknown adverse effects. In the study by Tipping et 
al., cardiovascular drugs accounted for more than one-third 
of the total amount of adverse drug events among patients 
aged 65 years and older (Tipping et al. 2006). Also the use of 
serum lipid modifying agents together with other 
medications and changes in body composition and body 
function that occur with age may increase the risk of 
clinically important adverse reactions (Routledge et al. 2004).  
There is not much population-based information available 
on cardiovascular drug use and age-related changes in 
elderly populations aged 75 years or more (Wills et al. 1996, 
Barat et al. 2000, Strandberg et al. 2001). Knowledge 
concentrating on these aspects is needed in order to 
guarantee safe and appropriate drug treatment. 
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2 Review of the literature 
2.1 DEFINING AGEING 
Ageing is defined mostly as a biological, psychological and 
social phenomenon. In the simplest definition, age is a 
chronological count of calendar years; in western countries 
ageing is usually measured in years (Stuart-Hamilton 2000). 
Biological ageing is associated with changes in the human 
organism and biological aging processes. The term describes 
the general state of a person’s body. Social age refers to the 
societal expectations of how people should behave at a 
particular chronological age (Jyrkämä 1995). Chronological 
age is simply a measure of how many years old a person is. 
However, age alone is often a poor indicator. The 
chronological age at which old age begins is often between 
6070 years; at around these years psychological and physical 
changes tend to manifest themselves. In addition, older 
persons are often divided into young elderly (i.e. 6075 
years), old elderly (i.e. 75+ years) and old-old (i.e. 85+ years) 
(Stuart-Hamilton 2000, Arinzon et al 2005). In this study age 
refers to chronological age. In the literature part the target 
population is limited to 65 years or older and in the study 
part the limit is 75 years or older.  
2.2 BLOOD PRESSURE, BLOOD LIPIDS AND AGEING 
Cardiovascular changes are common in aging persons (Table 
1). Age-related changes are most likely to be seen in the 
oldest old who have escaped cardiovascular outcomes earlier 
in their life (Lye & Donnellan 2000). It is often difficult to 
differentiate normal ageing from age-related pathology that 
is preventable or treatable. 
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Table 1. Changes in cardiac function with age 
  
Heart Maximal heart rate  
Maximal aerobic capacity  
Calcification of the valvular system  
Rigidity of the myocardium  
 
Blood vessels Vascular stiffness, aortic and large artery thickness  
Systolic blood pressure  
Susceptibility to blood pressure lowering during postural 
changes (= orthostatic hypotension)  
 
Fluid balance Fluid in the blood vessels  
Circulation in the kidneys  
 
Regulation 
systems 
Function of nervous reflex regulating heart and blood 
vessels  
 Susceptibility to blood pressure changes  
Changes in hormonal regulation systems 
 Heart response to adrenaline  
 Attenuation of the renin-angiotensin-aldosterone 
 system of the kidneys 
  
(Lye & Donnellan 2000, Tilvis & Aantaa 2001, Kostrzewski 2002)  
2.2.1 Blood pressure 
2.2.1.1 Hypertension 
Systolic blood pressure (SBP) increases linearly with age, but 
diastolic blood pressure (DBP) increases until about the age 
of 60 and decreases thereafter (Franklin et al. 1997). Thus, 
isolated systolic hypertension becomes the predominant type 
of hypertension in older persons. DBP is a more potent 
cardiovascular risk factor than SBP until the age 50, but 
thereafter SBP seems to be more important (Franklin et al. 
2001).  
Many age-related changes in physiology increase blood 
pressure and make the essence of hypertension in elderly 
persons different compared with the young or middle-aged 
(Table 2). An increase in peripheral vascular resistance is a 
typical feature of hypertension in the elderly (Vanhanen 
2001). An increase in arterial vascular stiffness, alterations in 
vessel structure and a decrease in elastin content may also 
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increase blood pressure. Thus, stroke volume does not 
change significantly with age, but arterial compliance 
declines, which contributes to an increase in systolic blood 
pressure (Supiano 2003).  
 
Table 2. Special characteristics of hypertension in the elderly 
 
Cardiac output  
Arterial compliance  
Renal blood flow  
Peripheral vascular resistance  
Renin concentration  
Bradycardia  
Orthostatic hypotension  
Tolerance of medications  
Underlying diseases  
 
(Vanhanen 2001, Kostrzewski 2002) 
 
The definition of high blood pressure has undergone many 
changes towards lower values during the last few decades. 
The European guideline classifies blood pressure in three 
stages (Table 3) (Graham et al. 2007). The Finnish guideline 
classifies blood pressure as elevated when SBP is ≥ 140 
mmHg or DBP is ≥ 90 mmHg. The newest guideline 
recommends lowering the target values: SBP < 140 mmHg 
and DBP < 85 mmHg (Käypä hoito: Kohonnut verenpaine 
2009). The recommendations for antihypertensive medication 
are based not only on blood pressure levels, but also on the 
presence of other risk factors and diseases, like the presence 
of established CVD, diabetes, renal disease or other target 
organ damage (Graham et al. 2007, Mancia et al. 2009).  
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Table 3. Classification of blood pressure levels 
Category  Systolic, 
mmHg 
 Diastolic, 
mmHg 
Optimal < 120 and < 80 
Normal < 130 and/or < 85 
High normal 130139 and/or 8589 
    
Hypertension    
Grade 1 (mild) hypertension 140159 and/or 9099 
Grade 2 (moderate) 
hypertension 
160179 and/or 100109 
Grade 3 (severe) hypertension ≥ 180 and/or ≥ 110 
    
Isolated systolic hypertension ≥ 140  and < 90 
(Graham et al. 2007, Käypä hoito: Kohonnut verenpaine 2009) 
 
The target levels of blood pressure in elderly persons are the 
same today as in younger persons, but the recommendation 
is to prescribe antihypertensive medication to elderly persons 
(80+ years) with a SBP value > 160 mmHg, with the goal of 
lowering it < 150 mmHg (Käypä hoito: Kohonnut verenpaine 
2009, Mancia et al. 2009). According to the guidelines and 
studies, orthostatic measurement should be done to all 
elderly persons before treatment is started due to the 
decreased reactivity of baroreflex during postural changes 
(Graham et al. 2007, Beckett et al. 2008, Käypä hoito: 
Kohonnut verenpaine 2009). 
Average blood pressure levels have decreased since the 
1970s in Finland in all age groups, also among elderly 
persons (Vartiainen et al. 2000, Kattainen et al. 2002, 
Vartiainen et al. 2010). In the Framingham Heart Study, the 
prevalence of hypertension (≥ 140/90 mmHg or treated) was 
63% in those aged 6079 years, and 74% in those aged 80 
years or older (Lloyd-Jones et al. 2005). In the NHANES 
19992004 study, 62% of the elderly aged ≥ 80 years were 
treated with antihypertensives (Ostchega et al. 2007). Among 
non-institutionalised individuals aged 65+, 62% were 
hypertensive (Brindel et al. 2006). In Finland, 41% of men and 
49% of women aged 65 year or more reported high blood 
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pressure or hypertension in 2007 (Aromaa & Koskinen 2002). 
In another Finnish population-based study, 76% of men aged 
≥ 80 years had SBP higher than 140 mmHg, and 
correspondingly, 84% of women. In those aged 85 years the 
percentages were 60% and 78%, respectively (Lehtonen et al. 
1995). 
2.2.1.2 Orthostatic hypotension  
Orthostatic hypotension (OH) is a physical finding defined 
by the American Autonomic Society and the American 
Academy of Neurology as a systolic blood pressure decrease 
of at least 20 mm Hg (systolic OH) or a diastolic blood 
pressure decrease of at least 10 mm Hg (diastolic OH) or both 
within three minutes of standing up form a supine position 
or during head up-tilting (the American Autonomic Society 
and the American Academy of Neurology 1996). In some 
patients a significant fall in blood pressure may not be noted 
until they stand for at least 10 minutes (delayed orthostatic 
hypotension) (Gibbons & Freeman 2006). 
Orthostatic hypotension has been observed in all age 
groups (Rose 2006), but its prevalence increases with age and 
it occurs more frequently in persons who are sick and frail 
(Lipsitz 1989, Tilvis et al. 1996, Shibao et al. 2007, Robertson 
2008). Hospitalisation, prolonged bed rest and diseases such 
as Parkinson’s disease are associated with OH (Mets 1995, 
Ooi et al. 1997, Gupta & Lipsitz 2007), as are haemodynamic 
conditions, such as hypovolemia and cardiac insufficiency 
and neurogenic causes such as multiple system atrophy and, 
for example, diabetic autonomic neuropathy (Bradley & 
Davis 2003). Other predisposing factors of OH are 
dehydration, poor nutrition and the bodily changes that 
occur with ageing (Robertson 2008). OH is negatively 
associated with body weight (Rutan et al. 1992, Ooi et al. 
1997). From 6% to 30% of home-dwelling elderly persons had 
OH (Rutan et al. 1992, Räihä et al. 1995, Masaki et al. 1998, 
Luukinen et al. 1999, Atli & Keven 2006), and it is even more 
prevalent in residential care (Ooi et al. 1997, Ooi et al. 2000, 
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Weiss et al. 2002, Poon & Braun 2005, Vloet et al. 2005, Weiss 
et al. 2006) (Table 4). The frequency of OH in cohorts of 
patients recruited through hospital Parkinson’s disease 
clinics ranges even up to 58% (Senard et al. 1997). The 
difference in prevalences varies due to factors like the 
definition of OH, the segment of the population (age, 
healthiness) and use of medications.  
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Orthostatic hypotension may be symptomatic or 
asymptomatic. Because the blood pressure criteria for 
diagnosing OH are arbitrary, it often correlates poorly with 
symptoms (Weiss et al. 2004). Symptoms of postural 
hypotension and OH may include dizziness, lightheadedness 
and cognitive impairment, and these symptoms can be risk 
factors for syncope and falls, which can lead to functional 
impairment (Rutan et al. 1992, Ooi, et al. 2000, Kario et al. 
2001, Heitterachi et al. 2002, Vloet et al. 2005).  
OH can be caused by many different factors. The causes of 
orthostatic hypotension can be broadly divided into acute 
and chronic. Acute OH is usually secondary to medication or 
blood or fluid loss and chronic orthostatic hypotension is 
frequently due to altered blood pressure regulatory 
mechanisms and autonomic dysfunction. The ability to 
maintain haemodynamic homeostasis during position 
changes becomes less effective with age. OH is frequently a 
consequence of an altered blood pressure regulatory 
mechanism and autonomic dysfunction like loss of buffering 
reflexes (Gupta & Lipsitz 2007). In healthy persons, muscle 
contraction increases venous return of blood to the heart 
through one-way valves that prevent blood from pooling in 
dependent parts of the body. If this compensatory 
mechanism remains insufficient, the baroreceptor reflex is the 
body's rapid response system for dealing with changes in 
blood pressure. The baroreceptor reflex is the body's rapid 
response system for dealing with changes in blood pressure. 
Baroreceptor sensitivity decreases with age and a larger 
change in blood pressure is needed to activate the 
baroreceptor system and produce the compensatory response 
(Supiano 2003). Attenuated baroreceptor sensitivity might be 
one reason for blood pressure variation in older persons. If 
blood pressure falls, such as in rising from a supine to a 
standing position, the baroreceptor firing rate decreases. 
Failure of the baroreceptor system to produce an adequate 
response to a sudden fall in blood pressure causes orthostatic 
hypotension. Acute hypotension results in a disinhibition of 
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sympathetic activity within the medulla, so that sympathetic 
activity increases. These autonomic changes cause 
vasoconstriction, tachycardia and positive inotropy. The 
latter two changes increase cardiac output and lead to a 
partial restoration of arterial pressure (Sparks & Rooke 1987). 
OH can also be caused by several medicines administered 
for other conditions, such as antihypertensives (Poon & 
Braun 2005), antidepressants (Liu et al. 1995, Poon & Braun 
2005), alpha-adrenergic blocking agents (Mets 1995, 
Souverein et al. 2003, Poon & Braun 2005), vasodilators like 
nitroglycerin, and medication for Parkinson's disease (Ooi et 
al. 1997). In addition, arterial stiffness plays an important role 
in OH (Boddaert et al. 2004, Gupta & Lipsitz 2007). Medicines 
are major non-neurogenic causes of orthostatic hypotension. 
OH may be more prevalent in elderly persons due to 
increased use of vasoactive medications. In the study by 
Poon & Braun, there was a significant relationship between 
the number of medicines used and the presence of OH (Poon 
& Braun 2005). Withdrawal of fall-risk-increasing medicines 
like psychotropics, i.e. antidepressants and sedatives, and 
cardiovascular medications i.e. diuretics and digoxin showed 
a significant reduction in OH in older people (van der Velde 
et al. 2007). 
The impact of OH on mortality is still under research. 
Some studies have concluded that it has no impact on 
vascular or nonvascular mortality (Tilvis et al. 1996, Weiss et 
al. 2006). In contrast, in some studies it has been associated 
with cardiovascular and all-cause mortality (Masaki et al. 
1998, Luukinen et al. 1999, Luukinen et al. 2004, Verwoert et 
al. 2008). The presence of OH has been a significant, 
independent predictor of five-year all-cause mortality. The 
degree of blood pressure drop corresponds linearly to the 
increase in mortality (Masaki et al. 1998). An association with 
mortality and morbidity has been reported even for blood 
pressure drops lower than those fulfilling the OH criteria 
(Masaki et al. 1998, Luukinen et al. 2004). The risk of 
cardiovascular disease and mortality was especially strong 
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among very old subjects with OH (Verwoert et al. 2008). A 
Finnish study reported a link between diastolic OH, but not 
systolic OH, and the prevalence of myocardial infarction 
(Luukinen et al. 2004). Hypotension with OH may be an early 
comorbid marker of primary incipient dementia (Yap et al. 
2008). In addition, OH seems to reflect a decline in overall 
health (Masaki et al. 1998). 
About 50% of elderly persons occasionally meet the 
criteria of orthostatic hypotension, and evaluation and 
therapy are primarily driven by symptoms (Robertson 2008). 
Because OH itself is not a disease, the first step in treating 
OH is to diagnose and manage the underlying cause. Patients 
with symptoms or without a specific cure often benefit from 
non-pharmacologic treatment like slow, careful changes in 
position and increases in salt and fluid intake (Lipsitz 1989, 
Shannon et al. 2002, Lahrmann et al. 2006). The mineral 
corticoid fludrocortisone is used by some patients to expand 
intravascular volume (Lipsitz 1989). 
2.2.2 Blood lipids 
Women’s cholesterol levels increase up to age 70 and decline 
thereafter. Men’s serum total cholesterol levels usually 
increase up to age 60 (Abbott et al. 1998, Primatesta & Poulter 
2000). Men’s triglyceride level increases up to age 60 and 
declines thereafter; in women it declines after 70 years. This 
effect is more prominent in women than in men, thus 
hypercholesterolemia is more common in elderly women 
than in elderly men (Kannel 1996, Tresch & Aronow 1999, 
Aromaa & Koskinen 2002). In the study by Abbott et al (1998) 
the levels of serum total cholesterol (S-TC) and serum low-
density lipoprotein cholesterol (S-LDLC) declined and the 
level of serum high-density lipoprotein cholesterol (S-HDLC) 
increased. The alterations in S-TC and S-HDLC levels may be 
expected to occur with advancing age regardless of risk 
factor status (Abbott et al. 1998). S-HDLC seems to protect 
elderly persons of all ages and both genders against 
cardiovascular disease (Cooney et al. 2009). 
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About half of all the elderly aged 75 years have 
atherosclerotic disease (Wenger 2007). The average S-TC level 
of men in the UK aged 75 years or more was 5.5 mmol/l and 
the S-HDLC level was 1.3 mmol/l. In women the values were 
6.3 mmo/l and 1.6 mmol/l, respectively (Primatesta & Poulter 
2000). In Finland, among the elderly aged 65 years or older, 
women have higher levels of S-TC and S-LDLC than men. Of 
woman aged 65 years or more, 39% had a S-TC level higher 
than 6.5 mmol/l. In men the respective proportion was 25%. 
Of women, 87% had a S-LDLC level ≥ 3.0 mmol/l and of men, 
82%. Eighteen percent of women and 37% of men had a S-
HDLC level < 1 mmol/l and 29% of the elderly had a 
triglyceride level ≥ 2.0 mmol/l (Aromaa & Koskinen 2002). In 
the population aged 75 years or more, S-LDLC values were 
higher among women than in men (average 3.4 to 3.5 mmol/l 
vs. 3.0 to 3.3 mmol/l), whereas S-HDLC levels among men 
were significantly lower (average 1.3 to 1.4 mmol/l vs. 1.6 
mmol/l) (Strandberg et al. 2003). 
2.2.3 Treatment guidelines for hyperlipidemia 
In Finland, like in other European countries, the 
recommended blood lipid level in the adult population is < 5 
mmol/l for S-TC, < 3 mmol/l for S-LDLC and > 1 mmol/l for S-
HDLC. In the latest guidelines, cholesterol levels should be 
lower in patients with risk factors (i.e. diabetes): < 4.5 mmol/l 
for S-TC and < 2.5 mmol/l for S-LDLC level (S-TC < 4.0 
mmol/l and S-LDLC < 2.0 mmol/l, if possible). In very-high-
risk patients (arterial disease with symptoms and diabetes), 
the S-LDLC level should be lower than 1.8 mmol/l (Graham 
et al. 2007, Käypä hoito: Dyslipidemiat 2009). In the 
American guidelines, the most important factor is S-LDLC, 
and it is the primary target of therapy. The updated version 
of the Adult Treatment Panel (ATP III guideline of the 
American Heart Association and the National Education 
Panel) points out that the LDL cholesterol level in high-risk 
patients (persons with CHD or CHD risk equivalents (non-
coronary forms of clinical atherosclerotic disease, diabetes or 
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multiple risk factors)) should be < 1.81 mmol/l (70 mg/dl) 
(Expert Panel on Detection, Evaluation, and Treatment of 
High Blood Cholesterol in Adults 2001, Grundy et al. 2004). 
Today there are no specific guidelines for the care of elderly 
persons. The guidelines accentuate that the first line of 
treatment is to change the way of life through a healthier diet 
and physical exercise before starting medication. In elderly 
persons, diet changes must be made carefully. No benefits of 
weight loss have been shown in elderly aged 65 years or 
more, and the risk of malnutrition is high (Käypä hoito: 
Aikuisten lihavuuden hoito 2006, Käypä hoito: Dyslipidemiat 
2009). ATP III points out that there is no age restriction when 
selecting persons with established coronary heart disease for 
LDL-lowering therapy. Older persons in the ATP III 
guideline include male persons aged 65 years or more and 
female persons aged 75 years or more. In contrast to the 
Finnish guidelines, the first line of therapy for older persons 
in the American guidelines is primary prevention and 
therapeutic lifestyle changes (incl. weight reduction and 
physical activity). In addition, LDL-lowering drugs can also 
be considered when older persons are at higher 
cardiovascular risk because of multiple risk factors (Expert 
Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults 2001). 
Treatment with lipid modifying agents can also be divided 
into primary and secondary prevention based on 
concomitant diseases and the total risk for cardiovascular 
outcomes.  Primary prevention includes healthy individuals, 
i.e. persons with adverse lifestyles without atherosclerotic 
disease or its symptoms (Käypä hoito: Dyslipidemiat 2009). 
The objective of coronary heart disease prevention in healthy 
high-risk persons is to reduce the risk of manifesting 
coronary heart disease (Wood et al. 1998). The objective of 
secondary prevention is to reduce the progression of 
atherosclerotic disease, the risk of disability and mortality, 
and to prolong survival in patients with coronary heart 
disease or other atherosclerotic disease (Wood et al. 1998). 
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The guidelines point out that the treatment decisions should 
always be based on the total risk. In Europe, one of the most 
commonly used risk assessments is the SCORE (Systematic 
Coronary Risk Evaluation) system, based on total 
cardiovascular risk. In SCORE the following risk factors are 
integrated: gender, age, smoking, SBP and S-TC or the S-
TC/S-HDLC ratio. SCORE shows the ten-year risk of fatal 
cardiovascular disease in high-risk regions of Europe, but it 
should be noted that the SCORE system is not applicable 
among patients aged 65 years or more (De Backer et al. 2003). 
In the United States and Canada the start of treatment is also 
based on total cardiovascular risk: the Framingham Cardiac 
Risk Score. It can be used to estimate the 10-year risk of 
developing hard cardiac heart disease (myocardial infarction 
and coronary death). The following risk factors are integrated 
into it: gender, age, smoking, SBP, S-TC, S-HDLC and if the 
person is currently on any medication to treat high BP 
(Expert Panel on Detection, Evaluation, and Treatment of 
High Blood Cholesterol in Adults 2001). The Framingham 
Risk Score also provides tools for estimating the 10-year risk 
of developing general cardiovascular disease. It contains the 
following predictors: age, diabetes, smoking, treated and 
untreated SBP, S-TC and S-HDLC (BMI can be used to 
replace lipids in a simpler model) (D'Agostino et al. 2008). 
The Framingham Risk Score is not applicable among patients 
aged more than 79 years. 
The most-used criteria for starting treatment are patients 
with established cardiac heart failure, peripheral artery 
disease or cerebrovascular atherosclerotic diseases. 
Treatment can be started for asymptomatic individuals who 
are at high risk of developing cardiovascular diseases 
because of multiple risk factors for developing a 
cardiovascular event or markedly raised levels of single risk 
factors like cholesterol or blood pressure, or diabetes mellitus 
with microalbuminuria. One reason to start therapy is if an 
individual has close relatives with early-onset atherosclerotic 
cardiovascular disease or asymptomatic individuals at 
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particularly high risk (Expert Panel on Detection, Evaluation, 
and Treatment of High Blood Cholesterol in Adults 2001, 
Käypä hoito: Dyslipidemiat 2009, Mancia et al. 2009). 
2.2.4 Trials on serum lipid modifying agents  
The proportion of elderly participants and their mean age in 
clinical trials has been low (Table 5). In most cases 
subpopulation analyses of the oldest old participants are not 
done due to the small number of old-old participants. Today 
the age range in clinical trials of elderly persons is between 65 
and 82 years. Similarly, the proportion of women is often 
underrepresented; in real life patients in the elderly 
population are more than twice as likely to be women than in 
clinical trials. High blood cholesterol levels among elderly 
persons have been studied mainly in studies concentrating 
on secondary prevention (Miettinen et al. 1997, Lewis et al. 
1998, Hunt et al. 2001, Heart Protection Study Collaborative 
Group 2002, Shepherd et al. 2002, Kjekshus et al. 2007). The 
impact of primary prevention on cardiac heart disease in 
older adults (> 75 years) without a history of cardiovascular 
events is insufficient (Shepherd et al. 2002, Ridker et al. 2008).  
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2.2.4.1 Primary prevention studies on the use of statins 
The PROSPER trial addressed the high-risk elderly 
population (age 7082 years) with existing vascular disease 
(secondary prevention) or at high risk of developing vascular 
disease (primary prevention). Primary prevention was part of 
the study and there was no statistical difference between the 
placebo and statin groups and cardiovascular outcomes 
(Shepherd et al. 2002). In contrast, in the JUPITER trial, 
apparently healthy people on rosuvastatin (median age 66) 
with CRP concentrations > 2.0 mg/l had significant reductions 
in ischemic vascular events as well as total mortality (Ridker 
et al. 2008). Unfortunately the follow-up period was only 1.9 
years. Due to the short follow-up, coincidence might have 
had an influence on the results of the JUPITER study. 
2.2.4.2 Secondary prevention trials on the use of statins 
Many studies have shown that using of statins reduces all-
cause mortality among patients with risk factors for vascular 
disease (Afilalo et al. 2008). The Scandinavian Simvastatin 
Survival Study (4S) was the first clinical trial to show 
significant reductions in total as well as coronary mortality 
among elderly persons using statins (Miettinen et al. 1997). 
The CARE and LIPID studies showed that elderly persons 
treated with statins had a lower risk for coronary events and 
of dying from coronary events. In the CARE study patients 
with myocardial infarction and a S-TC level < 6.2 mmol/l and 
a S-LDLC level of 3.04.5 mmol/l who were on pravastatin 
were associated with a lower risk for major coronary events 
and stroke (Lewis et al. 1998). In the LIPID study, patients 
with coronary heart disease and a S-TC level of 4.07.0 
mmol/l, pravastatin reduced the risk for all major 
cardiovascular events and all-cause mortality (Hunt et al. 
2001). The PROSPER trial addressed the high-risk elderly 
population (age 7082 years) with existing vascular disease 
(secondary prevention) or at high risk of developing vascular 
disease (primary prevention). There was no difference in all-
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cause mortality between the pravastatin and placebo groups, 
but in secondary prevention the risk for coronary disease 
mortality or non-fatal MI was lower in elderly persons on 
pravastatin (Shepherd et al. 2002). A new study on the use of 
rosuvastin in older patients with ischaemic heart failure 
showed that use did not reduce the primary outcome or the 
number of deaths from any cause despite having favorable 
effects on lipid levels, but it reduced the number of 
cardiovascular hospitalisations (Kjekshus et al. 2007). 
Comparable results were also observed in the GISSI-HF 
study on patients with heart failure treated with rosuvastatin 
(GISSI-HF Investigators 2008). 
2.2.5 High blood pressure and high cholesterol levels as 
risk factors 
For middle-aged patients with vascular disease, traditional 
cardiovascular disease risk factors like high serum 
cholesterol and high blood pressure are associated with 
greater all-cause and cardiovascular mortality (MacMahon et 
al. 1990, Stamler et al. 1999, Stamler et al. 2000). Also the 
benefits of cholesterol-lowering/blood pressure-lowering 
treatments are well documented in middle-aged populations 
(LaRosa et al. 1999, Ogden et al. 2000). There are several 
difficulties in interpreting mortality predictors in old age, 
and there are only a few population-based studies among 
elderly persons aged 75 years or more. Some studies have 
shown that, for example hypertension or 
hypercholesterolemia are associated with better prognosis in 
older persons and the association between lipid levels/blood 
pressure and total mortality are different in the elderly 
compared with the younger population (Mattila et al. 1998, 
Stamler et al. 1999, Stamler et al. 2000, Schatz et al. 2001). 
Some observational studies of persons aged 65 years or older 
suggest that not only cholesterol (Weverling-Rijnsburger et 
al. 1997, Song, Sung & Kim 2000, Schatz et al. 2001, Casiglia et 
al. 2003, Schupf et al. 2005, Tikhonoff et al. 2005, Spada et al. 
2007) but also blood pressure might be inversely associated 
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with total mortality (Mattila et al. 1988, Kronmal et al. 1993, 
Hakala  et al. 1997, Rastas et al. 2006, van Bemmel et al. 2006, 
Oates et al. 2007, Molander et al. 2008). With ageing the 
predictive power of these traditional risk factors seems to 
disappear or at least lose some of its predictive potency 
(Menotti et al. 2004). This is partly due to the selective 
survival (individuals with risk factors are likely to die at a 
younger age than those without) and survivor effect (leading 
to a surviving population with fewer risk factors)  (Tresch & 
Aronow 1999). Based on a large meta-analysis, it seems that 
the relative effect of total cholesterol and systolic blood 
pressure above 145 mmHg on ischaemic heart disease 
mortality attenuates in all age groups and the association 
between total cholesterol and total stroke mortality is inverse 
in the age group of 7089 years and among those with 
systolic blood pressure above 145 mmHg (Prospective 
Studies Collaboration et al. 2007). 
Sometimes the inverse association between blood pressure 
or serum total cholesterol and mortality has been interpreted 
to be due to confounding by chronic diseases such as 
dementia (Manolio et al. 1993, Guo et al. 1998). Still, some 
epidemiological studies have shown that an inverse 
association remains among the oldest old even when 
adjusted for co-morbid diseases (Kronmal et al. 1993, 
Weverling-Rijnsburger et al. 1997, Hakala et al. 1997, Schatz 
et al. 2001, Schupf et al. 2005, Rastas et al. 2006, van Bemmel 
et al. 2006, Oates et al. 2007, Molander et al. 2008). 
2.3 USE OF CARDIOVASCULAR MEDICATION 
Wholesale sales of cardiovascular drugs in Finland totaled 
230 million euro in 2007, which makes them the third largest 
group in terms of sales. The consumption of cardiovascular 
drugs increased by 8% from the year 2006 (Suomen 
lääketilasto 2008). In general, the use of diuretics decreased 
(1%). In contrast, the use of beta blocking agents (1%) and 
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calcium channel blockers (7%) increased in 2007. The biggest 
increase was in the newest group of cardiovascular 
medicines; the use of agents acting on the renin angiotensin 
system increased by 10%.  
2.3.1 Use of cardiovascular medication among elderly 
populations 
The amount of drugs in use has increased among both men 
and women, especially among persons aged 85 years and 
over (Jylhä 1994, Linjakumpu et al. 2002a, Linjakumpu et al. 
2002b, Jyrkkä et al. 2006). In Finland, cardiovascular 
medicines like antihypertensives have for decades been the 
most-used medication among elderly persons, reflecting the 
high prevalence of cardiovascular diseases (Nissinen et al. 
1989, Korhonen et al. 2008a). Overall, over half of the elderly 
population in Finland used cardiovascular medicines 
(Linjakumpu et al. 2002b). Similarly, cardiovascular drugs 
followed by central nervous system drugs are the most 
commonly used prescription drugs among the Danish and 
Swedish elderly (Barat et al. 2000, Rosholm et al. 1998, 
Jörgensen et al. 2001) and similar results have been reported 
in other European countries (Nobili et al. 1997) and the 
United States (Kaufman et al. 2002) (Table 6).  
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In the study by Fishkind et al. the most-used cardiovascular 
medicines among elderly persons were diuretics, beta 
blockers and calcium channel blockers (Fishkind et al. 1997). 
The use of acetylsalicylic acid (68.3% of men, 61.0% of 
women) and long-acting nitrates (54.7% and 52.9%, 
respectively) and beta blockers (52.4% and 54.7%, 
respectively) is high among elderly persons with coronary 
disease (Strandberg et al. 2001). In the USA, the medicines 
most used by the elderly aged 75+ were acetylsalicylic acid 
(53.8%), statins (25.3%) and beta blockers (19.6%) (Nahin et 
al. 2009). In Finland, the most-used cardiovascular medicines 
among centenaries were diuretics (59% of all users) 
(Korhonen et al. 2008a). 
The use of digitalis in the treatment of heart failure has 
decreased over the years.  In 1992 and 2000 it had almost 
disappeared as an alternative in the treatment of heart failure 
(men aged 70 years 4%, women aged 70 years 0%) (Lernfelt et 
al. 2003). In Finland, 10% of the elderly aged 100 years or 
older used digitalis (Korhonen et al. 2008a). In the USA 17% 
of the study subjects used digitalis (Fishkind et al 1997). In 
Canada, 32% of long-term residents with heart failure used 
digitalis (Misiaszek et al. 2005). 
In the study by Putnam et al. (2004) there was a difference 
in the use of beta blockers between genders (men used more) 
(Putnam et al. 2004). In a Finnish study women more often 
used ACE inhibitors, diuretics and digitalis (Strandberg et al. 
2001). In comparison, in 1989 women used more diuretics, 
but beta blockers were more common among men in Finland 
(Nissinen et al. 1989). In the Framingham study, the use of 
thiazide diuretics increased in patients older than age 60 
years, with women using them more often than men (Lloyd-
Jones et al. 2005). In many studies there were no significant 
differences between genders in the use of blood pressure and 
cholesterol lowering medicines (Chen et al. 2001, Brekke et al. 
2006).  
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2.3.2 Use of serum lipid modifying agents  
The use of serum lipid modifying agents, especially statins 
(HMG CoA reductase inhibitors), has increased rapidly 
among elderly persons in Finland and other western 
countries, and the trend in current statin use seems to be 
moving towards more extensive use among elderly persons 
(Walley et al. 2005) (Table 7). In 19711972 only 1% of men 
aged 70 years or more and 3% of women aged 70 years or 
more used serum lipid modifying agents (Lernfelt et al. 2003). 
Since the 1990s the use of serum lipid modifying agents has 
increased rapidly and mostly among the oldest old, peaking 
in the age group of 7079 years in both sexes (Hartz et al. 
2007). In 2000 more than 10% of elderly persons used 
cholesterol-lowering medication. The use of serum lipid 
modifying agents increased tenfold during these years 
among men and threefold among women (Lernfelt et al. 2003, 
Carroll et al. 2005, Raymond et al. 2007). 
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The use of serum lipid modifying agents has increased also in 
Finland (Martikainen et al. 1997, Ruokoniemi et al. 2008). In 
2007 lipid modifying agents were used 20% more than in 
2006 (Suomen lääketilasto 2008). One-year prevalence 
increased forty-fold from 1995 to 2005, from 7.0 per 1000 to 
283.3 per 1000 in males and from 6.7 per 1000 to 264.4 per 
1000 in females among persons aged at least 75 years 
(Ruokoniemi et al. 2008).  One out of three elderly persons 
aged 65 years or more used serum lipid modifying agents 
(Aromaa & Koskinen 2002, Savolainen 2007). 
2.4 ADVERSE DRUG EVENTS ASSOCIATED WITH THE USE 
OF CARDIOVASCULAR MEDICATIONS   
Treatment of cardiovascular diseases with multiple, 
concomitant medications to achieve cardiovascular benefits 
must be balanced against potential harm among elderly 
persons. With ageing, all aspects of pharmacokinetics and 
pharmacodynamics (absorption, distribution, metabolism, 
excretion and target organ sensitivity) may be affected and 
the possibility of adverse drug events may increase (Ewing 
2002, Cassel 2003) (Table 8). 
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Table 8. Adverse effects of cardiovascular medicines in elderly populations  
Medicine group Adverse effect 
Cardiac glycosides Cardiac arrhythmias 
 States of confusion, nausea, vomiting, 
blurred vision (halos around objects; 
yellow, green, white) 
  
ACE inhibitors Cough, dry mouth, dizziness, rash 
Hyperkalemia, hypoglycaemia 
  
Angiotensin II antagonists Dizziness 
 Hypotonia, weakness 
  
Beta blocking agents Heart failure, bradycardia, dizziness 
 Intermittent claudication 
  
Calcium channel blockers Constipation, oedema, weakness 
  
  
Vasodilatators Hypotonia 
  
Diuretics Disorders of salt balance, hypokalemia, 
hypomagnesemia 
 Dehydration 
 Fatigue, dizziness, orthostatic symptoms 
 Impaired glucose tolerance 
  
Nitrates Headache, orthostatic symptoms 
  
HMG-CoA reductase inhibitors 
(statins) 
Constipation, nausea, diarrhoea 
Myalgia (muscle pain, aching, weakness) 
 Myositis (myalgia + elevated serum 
levels of creatine kinase) 
 Rhabdomyolysis 
  
(Tilvis & Aantaa 2001, Ewing 2002, Tomlinson & Mangione 2005, Aronow & Frishman 2007, 
Pharmaca Fennica 2009) 
 
It has been shown that medicines used mainly for 
hypertension are associated with adverse events apart from 
their cardiovascular outcomes. The current guidelines 
suggest the use of several medications, if needed, to control 
hypertension (Chobanian et al. 2003, Käypä hoito: Kohonnut 
verenpaine 2009). Every tenth hypertensive patient reported 
symptoms related to antihypertensive medication 
spontaneously, and 20% did so when asked for symptoms 
(mean age of patients, 64 years) (Kumpusalo et al. 1997). In 
the same study, 80% of hypertensive patients reported at 
29 
 
 
least one symptom and an average of four symptoms. 
Dizziness, headache, muscular cramps, cough and faintness 
are adverse drug events perceived by patients and that are 
associated with antihypertensive medications. With 
increasing age, symptoms like dry mouth, dizziness during 
postural changes, other dizziness, urinary incontinence and 
constipation increased (Kumpusalo et al. 1997).  
Higher cumulative exposure to antihypertensive 
medications has been associated with adverse events on 
physical performance, but not on cognition or depression 
(Agostini et al. 2007). In the study by Euser SM et al., for 
persons aged 65 to 74, higher baseline systolic and diastolic 
blood pressure were related to worse cognitive function 11 
years later, but at older ages (75+) higher SBP and DBP were 
related to better cognitive function 11 years later. The effect 
of blood pressure on cognition was strongest in the highest 
age group (aged 85) (Euser et al. 2009). In the study by 
Tipping et al., cardiovascular drugs accounted for 36% of 
total adverse drug events among patients aged 65 years and 
older (Tipping et al. 2006).   
The use of serum lipid modifying agents together with 
polypharmacy and impaired renal and hepatic function and 
certain concomitant medications may increase the risk of 
clinically important adverse events (Routledge et al. 2004). 
The most common side event is skeletal myopathy, with 
symptoms ranging from pain and fatigue to serious 
rhabdomyolysis. All statins are associated with the adverse 
effects of myopathy (Pasternak et al 2002), and symptoms of 
myopathy may occur at any time after initiation of statin 
therapy. Factors that may increase the risk of myopathy are, 
for example, age > 80 years, being female and frailty (Fig 1). 
In general populations, patients who may benefit most from 
statin therapy often are patients with comorbidities and 
multiple medications. Due to this, they also are at high risk 
for myopathies and other adverse effects (Ballantyne et al. 
2003). Myositis refers to muscle symptoms, as myositis with 
increased levels of creatine kinase (CK) and muscle-related 
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pathologies is most often confirmed by serum CK levels 
(Tomlinson and Mangione 2005). However, muscle weakness 
or muscle pain has also been reported without CK elevation 
suggesting that the CK level may not be an adequate test for 
muscle pathology (Phillips et al 2002). In clinical trials with 
strict inclusion criteria and frequent monitoring, the 
incidence of muscle problems is reported to be low. The 
incidence of severe myopathy is low, occurring in less than 
0.1% of patients receiving statin monotherapy (Staffa et al. 
2002). But, it has been indicated that less serious adverse 
effects, like muscle pain and weakness, are underreported, 
and their incidence increases among patients taking multiple 
medications and among those with multiple risk factors, and 
it may be up to 10.5% in the general population (Bruckert et 
al. 2005). In addition, the incidence of less severe muscle 
complaints is not well defined among the elderly population 
(Thompson et al. 2003). In the study by Buettner et al., in 
adults aged ≥ 40 years, statin users were significantly more 
likely to report musculoskeletal pain than were non-users 
(Buettner et al. 2008). 
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Figure 1. Factors that may increase the risk of myopathy in statin users 
(Tomlinson S & Mangione K 2005) 
32 
 
 
3 Aims of the study 
The general aim of this study was to investigate the use of 
cardiovascular medicines and outcomes of treatment among 
elderly persons aged 75 years or more. 
 
The specific aims of this study were: 
 
1. To analyse the use of cardiovascular medication 
among elderly persons according to age and sex and 
other socio-demographic background variables. 
2. To analyse the use of serum lipid modifying agents 
with special reference to concomitant cardiovascular 
risk factors and the effects of treatment on lipid levels.  
3. To examine the relationship between serum total 
cholesterol and six-year all- cause mortality in elderly 
persons when adjusted for concomitant diseases 
4. To study postural changes in blood pressure and 
prevalence of orthostatic hypotension. In addition, to 
find associations between the use of medications and 
orthostatic hypotension. 
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4 Material and methods 
The present thesis is comprised of two prospective, 
longitudinal, population-based studies focusing on the 
clinical epidemiology of diseases, functional capacity and use 
of medicines in a population of elderly persons aged 75 years 
or older. 
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4.1 STUDY POPULATION  
The study population consists of two different study 
populations: Kuopio 75+ (work I & III) and the GeMS study 
(work II & IV), both carried out in the City of Kuopio, 
Finland. 
4.1.1 Kuopio 75+ study (Work I, III)  
The Kuopio 75+ study is a prospective, population-based, 
multidisciplinary health study focusing on the clinical 
epidemiology of diseases, medication and functional capacity 
in elderly persons aged 75 years or older. All subjects aged 75 
years or more living in the City of Kuopio on January 1, 1998 
(N = 4518), were eligible. From this population a random 
sample of 700 persons was drawn. The final cohort included 
601 participants (86%): 79 declined to participate, 15 died 
before the examination and five could not be contacted. The 
final cohort attended a structured clinical examination and an 
interview conducted by a geriatrician and a trained nurse. Of 
these 601 clinically examined subjects 74% were females. At 
the baseline 87% (n = 523) were home-dwelling and 13% (n = 
78) lived in institutional care. The follow-up survey was 
conducted in 2003 with 339 participants (females 75%) in the 
same way as in 1998, except that there was no clinical 
examination by a physician. The loss of participants due to 
death (n = 233) during the follow-up period was significant, 
and in addition 29 participants declined to participate or 
could not be reached. Of the surviving persons, 85% (n = 289) 
were home-dwelling and 15% (n = 50) lived in institutional 
care. 
In work III, out of 523 home-dwelling participants, 30 who 
used lipid modifying agents and three persons with missing 
data on cholesterol and blood pressure measurement were 
excluded. Thus the final sample consisted of 490 home-
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dwelling elderly who were examined in 1998. The mean age 
of the participants was 81 years and 72% were females. 
4.1.2 GeMS study (II, IV)  
The GeMS study (Geriatric Multidisciplinary Strategy for 
Good Care of the Elderly) consisted of all the inhabitants, 
whether living in an institution or at home, in the city of 
Kuopio in eastern Finland who were aged 75 years or older 
on November 1, 2003. From this population, a random 
sample of 1000 persons was drawn. 
In the GeMS study the subjects were randomised into 
intervention (n = 500) and comparison (n = 500) groups. Of 
the randomised subjects, 162 persons declined to take part in 
the survey, 55 died before the examination and two moved 
away. The participation rate was 78% (n = 781) in the entire 
population, 81% (n = 404) in the intervention group and 75% 
(n = 377) in the comparison group. 
The final study population attended a structured clinical 
examination and an interview conducted by a trained nurse 
in 2004. Physiotherapists tested their functional capacity, 
strength and balance.  In 2006, 116 participants had died 
before the examination, one had moved away, and seven 
persons declined to take part in the survey. The remaining 
657 participants attended a similar examination as in 2004.  
In work IV, of all the examined elderly persons in 2004 (n 
= 781), we excluded those in institutional care (n = 82) and the 
home-dwelling elderly without an orthostatic test (n = 46). 
Work IV is based on information from the 653 home-dwelling 
elderly with an orthostatic test. Of the participants, 70% were 
females and the mean age of our participants was 81 years. 
Work II is based on information from all the elderly 
persons examined in 2004 and 2006 with cholesterol 
measurements (n = 622). Of all the elderly persons examined 
in 2004 and 2006 (n = 657), seven did not have a cholesterol 
measurement in 2004, 18 did not have a cholesterol 
measurement in 2006 and ten did not have a cholesterol 
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measurement in neither 2004 nor 2006. The mean age of the 
participants was 80 years and 71% were females.  
4.2 METHODS 
4.2.1 Methods in the Kuopio 75+ Study (I, III) 
The data for the Kuopio 75+ study were collected by means of 
interviews, clinical examinations and clinical tests. A trained 
nurse at the outpatient clinic of a municipal hospital 
interviewed the participants about their use of medicines and 
recorded the medicines they were currently taking. The 
participants were also asked to bring their prescriptions and 
medicine containers with them to the examination. In 
addition, a geriatrician reviewed the medication and 
examined the subjects’ overall physical and mental health. A 
close relative or a caregiver gave the required information if 
the participant could not answer the questions. If a 
participant was unable to visit the municipal hospital, a nurse 
and a geriatrician visited the home to perform the interview 
and examination and to check the use of medication.  
To collect the data, medical records from the municipal 
health centre, home nursing service, local hospitals and the 
Kuopio University Hospital were also available. Mortality 
data were obtained from Statistics Finland, which is the 
National Health Register Authority in Finland. Life span was 
calculated from the date of examination in 1998 to 31.12.2003. 
There was no loss to follow-up. 
4.2.2 Methods in the GeMS Study (II, IV) 
The basic demographic and clinical data were collected by 
means of interviews and measures (i.e. cholesterol). A trained 
nurse interviewed all the study participants about their 
health and health behaviour. The use of medicines was asked 
from the participants and the medicines they were currently 
taking were recorded. The participants were also asked to 
bring their prescription forms and medicine containers with 
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them to the interview. A Comprehensive Geriatric 
Assessment (CGA) of the subjects randomised into the 
intervention group was done yearly. In the GeMS study, 
physicians who were trainees in geriatrics, trained nurses 
and physiotherapists did the CGA. The CGA was not 
specifically aimed at cardiovascular risk factors or serum 
lipids. There were no differences in the use of serum lipid 
modifying agents or cholesterol levels between the 
intervention and comparison groups during the years 
20042006. As there were no differences, we combined the 
study groups in work III. If the person him/herself could not 
answer the questions, a relative or a caregiver gave the 
required information. If the participant was unable to visit 
the clinic, a trained nurse made a home visit. Medical records 
from the municipal health centre, home nursing service, local 
hospitals and Kuopio University Hospital were also 
available. To define concomitant diseases, we used the 
National Insurance Institution Special Refund Registers for 
2003 and 2005. 
4.3 VARIABLE DEFINITIONS 
Use of medicines 
Both regularly and irregularly taken prescribed and non-
prescribed medicines were recorded. If a medicine was taken 
daily or at regular intervals, it was recorded as being in 
regular use. If it was taken only when needed, it was 
recorded as being in irregular use. The medicines were 
classified according to the Anatomic Therapeutic Chemical 
(ATC) classification system, version 2004, recommended by 
the World Health Organization (WHO) for drug utilisation 
studies. (IIV)  
Self-rated health 
In assessing self-rated health, the participants were asked to 
grade their health as good, fairly good, moderate, fairly poor 
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or poor. For the analyses, the participants with good or fairly 
good health were combined as having good health and the 
participants with fairly poor or poor health were combined as 
having poor health and thus the final classification was good, 
moderate and poor. (III) 
Cardiovascular medicines 
According to the ATC classification cardiovascular medicines 
(C) include cardiac therapy and medicines used mainly for 
hypertension, diuretics, beta blocking agents, calcium 
channel blockers and agents acting on the renin-angiotensin 
system. Preventive medication for cardiovascular diseases 
includes lipid modifying agents, low-dose aspirin and 
warfarin. In counting the number of cardiovascular 
medicines in use, fixed combinations of two different agents 
were counted as one medicine. (I) 
Orthostatic hypotension 
The criteria for orthostatic hypotension (OH) were those 
defined by the American Autonomic Society and the 
American Academy of Neurology: a systolic blood pressure 
decrease of at least 20 mm Hg (systolic OH) or a diastolic 
blood pressure decrease of at least 10 mm Hg (diastolic OH) 
within three minutes of standing up (American Autonomic 
Society and the American Academy of Neurology 1996). (IV) 
Serum lipid modifying agents 
According to the ATC classification, serum lipid modifying 
agents (C10) included cholesterol and triglyceride reducers 
HMG CoA reductase inhibitors (statins, C10AA). In addition, 
it included fibrates (C10AB), bezafibrate (C10AB02), bile acid 
sequestrants (C10AC), cholestyramine (C10AC01) and other 
lipid modifying agents (C10AX) and ezemibid (C10AX09). 
(II) 
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Serum total cholesterol  
Serum total cholesterol was measured once by the 
laboratorian in the Kuopio University Hospital after 12-hour 
fasting. All serum total cholesterol assays were analyzed in 
the Kuopio University Hospital laboratory using standard 
enzymatic techniques (II, III) (Käypä hoito: Dyslipidemiat 
2009). To determine if cholesterol levels had changed during 
the study period, the difference between levels had to be 
greater than +/- 0.2 mmol/l for total and LDL cholesterol 
levels and greater than +/- 0.1mmol/l for HDL cholesterol 
level. (II) 
Concomitant diseases 
The Social Insurance Institution Special Refund Register was 
used in 2003 and 2005 to define concomitant diseases. The 
participants were classified as having coronary artery 
disease/diabetes mellitus/hypertension if they were entitled 
to special refunds for coronary artery disease/diabetes 
mellitus/hypertension before the examination. The subgroup 
with no risk for cardiovascular outcomes included non-
smoking elderly persons without special refunds for diabetes 
mellitus, coronary artery disease and hypertension or any 
diagnosis of these diseases. (III) 
 4.4 DATA ANALYSIS 
Statistical analyses in this doctoral thesis were performed 
with SPSS 11.5 and 14.0 (Statistical Package for Social 
Sciences). The statistical tests were two-sided and the 
criterion of statistical significance was p < 0.05. 
The results in work I are presented as proportions of 
medicine users and mean numbers (± 95% CI) of medicines 
used. McNemar’s test was used to analyse the statistical 
significance of changes in medicine use between the surveys 
in 1998 and 2003. The statistical significance of differences in 
categorical variables was analysed using the chi-square test. 
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In addition, in work III the statistical significances of 
differences between exposures groups were tested using the 
Kruskal-Wallis test, and in work II continuous variable 
differences were analysed using the non-parametric Mann-
Whitney U-test. The T-test was used to analyse the 
differences in pulse pressures between the OH groups in 
work IV. In work II, data for total, HDL and LDL cholesterol 
levels are presented as the mean ± SD for the baseline 
examination in 2004 and the follow-up examination in 2006. 
The two-sided non-parametric Wilcoxon test was used to 
assess the statistical significance of changes in cholesterol 
levels during the study period.  
The Kaplan-Meier method was used to estimate survival 
and compared using the log-rank test. The association 
between S-TC and mortality was analysed using the Cox 
proportional hazards model. A supplementary analysis a 
propensity score (PS) for each participant in the Cox model 
was included. The PS was estimated with a multinomial 
logistic regression model that included the following 
variables: age (continuous variable), atrial fibrillation, 
dementia, NYHA classification, systolic blood pressure 
(continuous variable), use of loop diuretics, Mini-Mental state 
examination score, sex, self-reported health, diabetes 
mellitus, history of cancer, valvular insufficiency, history of 
hypertension, myocardial infarction, bypass operation, use of 
long-acting nitrates, use of blood pressure-lowering 
medication, obstructive pulmonary disease, Parkinson’s 
disease, heart failure (Boston criteria). In the PS-adjusted 
model, coronary disease variables were included 
individually. 
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4.5 ETHICAL CONSIDERATIONS 
Written informed consent was obtained from the study 
participants or their caregivers and relatives. The Kuopio 75+ 
study and the GeMS study were approved by the Ethics 
Committee of the Hospital District of Northern Savo and the 
University Hospital of Kuopio. 
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5 Results 
5.1 PREVALENCE OF CARDIOVASCULAR MEDICINES USE 
(I) 
Regular use of cardiovascular medicines increased during the 
years 19982003 from 80% to 87% (p < .001) among the study 
population (n = 339). The number of medicines used ranged 
from 0 to 8. The mean number of regularly used 
cardiovascular medicines increased from 2.1 (95% CI 1.92.3) 
to 2.7 (95% CI 2.52.9, p <.001) during the follow-up period. 
The use of three or more cardiovascular medicines increased 
especially with advanced age (Table 10).  
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5.1.1 Use of cardiovascular medicines 
The most-used cardiovascular medicines in both years were 
beta-blocking agents.  In 2003 every other participant used at 
least one beta-blocking agent. The use of low-dose aspirin 
was also high (Table 11). Among the medicines used mainly 
for hypertension, the use of diuretics, beta blockers and ACE 
inhibitors and AT 1 receptor antagonists increased 
significantly during the follow-up period (p < .001).  The 
most-used group of cardiac therapies was long-acting 
nitrates. The use of cardiovascular medicines increased 
among both men and women.  In 1998, 32% of women and 
14% of men used diuretics. In contrast, the use of low-dose 
aspirin was more common among men (49% vs. 36%) in 1998. 
In 2003 there was no significant differences between genders. 
According to age, the proportion of ACE inhibitor and AT 
1 receptor antagonist users increased significantly (from 20% 
to 28%, p < .001) among the youngest age group. Among the 
oldest old (85+), the proportion of diuretic users doubled 
during the study period (from 31% to 62 %, p < .001). 
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5.2 CHOLESTEROL VALUES AND USE OF SERUM LIPID 
MODIFYING AGENTS (I, II, III)  
5.2.1 Use of serum lipid modifying agents 
In the Kuopio 75+ study, only 7% of all the elderly persons 
used serum lipid modifying agents. The corresponding 
proportion in 2003 was 12% (Table 12). There was no 
difference between genders in the use of serum lipid 
modifying agents. In the GeMS study, the use of serum lipid 
modifying agents increased during the study period from 
30% to 34% among all the study participants. In 2004, 31% of 
men used serum lipid modifying agents and 29% of women. 
The use of serum lipid modifying agents was more common 
among men also in 2006 (38% vs. 33%).  
 
Table 12. Use (%) of serum lipid modifying agents among the study populations  
Study Study 
year 
Age at study baseline 
  7579 8084 85+ Total 
  % % % % 
Kuopio 75+ 1998 11 5 2 7 
 2003 17 8 6 12 
      
GeMS 2004 36 30 12 30 
 2006 41 36 13 34 
 
The use of serum lipid modifying agents increased among 
high-risk patients. Still, among those with hypertension the 
prevalence of use was only 34% in 2006 (Table 13).  
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Table 13. Use of serum lipid modifying agents in 2004 and 2006 according to 
demographics and concomitant cardiovascular risk factors 
 User in 
2004 
n (%) 
 User in 
2006 
n (%) 
Age at baseline 
 7579 
 80-84 
 85+ 
 
112 (36) 
58 (30) 
14 (12) 
Age at baseline 
 7579 
 8084 
 85+ 
 
130 (41) 
68 (36) 
15 (13) 
Gender 
 Women 
 Men 
 
128 (29) 
56 (31) 
Gender 
 Women 
 Men 
 
143 (33) 
70 (38) 
Hypertension 
 No (n=375) 
 Yes (n=247) 
 
109 (29) 
75 (30) 
Hypertension 
 No (n=365)  
 Yes (n=257) 
 
125 (34) 
88 (34)  
CADa 
 No (n=431) 
 Yes (n=189) 
 
82 (19) 
101 (53) 
CADa 
 No (n=414) 
 Yes (n=206) 
 
99 (23) 
117 (57) 
Diabetes  
 No (n=584) 
 Yes (n=36) 
 
168 (29) 
15 (42) 
Diabetes 
 No (n=579) 
 Yes (n=41) 
 
191 (33) 
21 (51) 
Smoking* 
 Non-smoker (n=431) 
 Former smoker (n=164) 
 Current smoker (n=21) 
 
126 (29) 
48 (29) 
9 (43) 
Smoking* 
 Non-smoker (n=441) 
 Former smoker (n=158) 
 Current smoker (n=18) 
 
142 (32) 
60 (38) 
10 (56) 
CVD risk factorsb 
 0 (n=125) 
 1 (n=301) 
 2 (n=77) 
 3 or more (n=13) 
 
21 (17) 
98 (33) 
39 (51) 
8 (62) 
CVD risk factorsb 
 0 (n=100) 
 1 (n=311) 
 2 (n=85) 
 3 or more (n=14) 
 
14 (14) 
114 (37) 
46 (54) 
10 (71) 
    
a CAD= coronary artery disease 
b risk factors for cardiovascular outcomes incl. diabetes, coronary artery disease, hypertension and   
current smoker 
* four missing values in 2004 and three in 2006  
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The most-used statin in the GeMS study was simvastatin (Fig 
2). There was no difference between genders in the use of 
serum lipid modifying agents.  
 
44 %
19 %
15 %
9 %
13 %
51 %
18 %
13 %
6 %
12 %
Simvastatin Atorvastatin Lovastatin
Fluvastatin Other*
2004
2006
 
* incl. Pravastatin, rosuvastatin bezafibrate, cholestyramine, research medicine  
 
Figure 2. Use of different serum lipid modifying agents in 2004 and 2006 among 
the elderly persons using cholesterol-lowering medication 
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5.2.2 Cholesterol levels in 2004 and 2006 
The mean serum total cholesterol (S-TC) and serum low-
density lipoprotein levels tended to decrease (p < .001), while 
the level of serum high-density lipoprotein increased            
(p = .049) among all the examined elderly during the follow-
up (Fig 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Serum total (S-TC), low-density (S-LDLC) and high-density (S-HDLC) 
lipoprotein levels among all the examined elderly persons in 2004 and 2006 
   
 
Women had higher S-TC (p < .001), S-LDLC (p < .05) and S-
HDLC (p < .001) levels than men in both years. In addition, 
the cholesterol levels varied during the study period 
according to concomitant diseases and the number of risk 
factors (Table 14). 
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The decrease in cholesterol levels was most obvious among 
new serum lipid modifying agents users (non-user in 2004, 
user in 2006). Among those who stopped using them (user in 
2004, non-user in 2006), cholesterol levels increased. 
5.2.3 Cholesterol levels and all-cause mortality  
The study participants were divided into thirds based on 
serum total cholesterol (S-TC) levels. The participants with S-
TC levels < 5 mmol/l tended to be older, male, had lower 
systolic blood pressure and more commonly used loop 
diuretics and more commonly suffered from diseases such as 
dementia, diabetes mellitus, asthma/COPD and heart 
diseases (Table 15). The participants in the lowest third (< 5 
mmol/l) had the highest risk of death (Fig 4).  
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Figure 4. Serum total cholesterol (S-TC) and mortality using Kaplan-Meier 
survival analysis (Log rank p < 0.001) 
 
S-TC ≥ 6mmol/l 
S-TC =5-5.9mmol/l 
S-TC < 5mmol/l 
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When S-TC treated as a continuous variable, the age- and 
sex-adjusted HR of death for each 1 mmol increase in S-TC 
was 0.78 (95% CI 0.680.89). In the multivariable analysis, the 
HR of death for a 1 mmol increase in S-TC was 0.82 (95% CI 
0.700.95). In addition, age, dementia, use of loop diuretics 
and atrial fibrillation were significantly associated with the 
risk of death (Table 16).   
 
Table 16. Significantly associated hazard Ratios (HR) of death among the 
participants (n = 490) calculated from Multivariate Cox Proportional Hazards 
Models 
Risk Factor HR 95 % CI P-value 
Serum total 
cholesterol 
 
0.82 0.700.95 .008 
Age 
 
1.12 1.081.16 < .001 
Dementia 
 
2.71 1.843.98 < .001 
Use of loop diuretics 
 
1.98 1.342.94 < .001 
Atrial fibrillation 1.60 1.092.37 .018 
    
 
When S-TC < 5 mmol/l was used as the reference value, an 
inverse association between S-TC and mortality was seen in 
the age- and sex-adjusted, multivariable analysis and 
propensity score-adjusted model (Table 17). When adjusted 
for sex and age, an inverse association between S-TC and 
mortality was seen in the participants without concomitant 
diseases, i.e. dementia, stroke, obstructive pulmonary disease 
and no history of hypertension or cancer. High serum total 
cholesterol (≥ 6 mmol/l) was associated with decreased 
mortality in the participants with systolic blood pressure < 
140 mmHg. In the participants with systolic blood pressure ≥ 
140 mmHg, the association was attenuated but significant 
(age- and sex-adjusted HR = 0.59, 95% CI=0.360.98). 
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Table 17. Hazard ratios (HR) of death among the participants according to serum 
total cholesterol (S-TC) thirds calculated from Multivariate Cox Proportional 
Hazards Models  
S-TC HR Model 1* HR Model 2† HR Model 3‡ 
< 5 mmol/l 1 (ref) 1 (ref) 1 (ref) 
55.9 mmol/l 0.57 (95 % CI 
0.400.80) 
0.62 (95 % CI 
0.420.93) 
0.57 (95 % CI 
0.380.84) 
≥ 6 mmol/l 0.48 (95 % CI 
0.330.70) 
0.59 (95 % CI 
0.390.89) 
0.42 (95 % CI 
0.280.62) 
    
Cox proportional hazard model 
* adjusted for age and sex 
† adjusted for age, atrial fibrillation, dementia, use of loop diuretics, stroke. Variables in the initial 
model: systolic blood pressure (continuous variable), sex, self-reported health, diabetes mellitus, 
history of cancer, valvular insufficiency, coronary disease (incl. myocardial infarction, bypass 
operation or coronary angioplasty), use of long-acting nitrates, use of blood pressure-lowering 
medication, obstructive pulmonary disease, NYHA classification (New York Heart Association 
functional classification) 
‡ propensity-score-adjusted model. Variables in the model: age (continuous variable), atrial 
fibrillation, dementia, NYHA classification, systolic blood pressure (continuous variable), use of 
loop diuretics, Mini-Mental state examination score, sex, self-reported health, diabetes mellitus, 
history of cancer, valvular insufficiency, history of hypertension, myocardial infarction, bypass 
operation, use of long-acting nitrates, use of blood pressure-lowering medication, obstructive 
pulmonary disease, Parkinson’s disease, heart failure (Boston criteria)  
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5.3 ORTHOSTATIC HYPOTENSION (IV) 
5.3.1 Postural changes in blood pressures 
In work II, almost 70% of all the examined elderly 
experienced a systolic blood pressure drop in the orthostatic 
test after one minute standing, and 60% did so after three 
minute standing. Diastolic blood pressure dropped in 39% of 
the elderly persons after one minute of standing and in 32% 
after three minute of standing. 
 
5.3.2 Prevalence of orthostatic hypotension 
Orthostatic hypotension (OH) was recorded in as much as 
34% of the study population (Fig 5). The prevalence of OH 
was 31% among those aged 7579, 35% among those aged 
8084 and 40% among the oldest old (85+).  Only the 
combination of systolic and diastolic OH increased 
significantly with age (p < .05). There was no difference 
between genders in the prevalence of OH.  
 
 
Figure 5. Prevalence of different types of OH among all the elderly persons 
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5.3.3 Orthostatic hypotension and the use of medicines 
The association between the number of medicines in regular 
use and the prevalence of OH was statistically significant.    
(p < .05, Table 18). The more medicines in regular use, the 
more common was OH. There was no association between 
any particular medicine and OH. There was no association 
between the number of irregularly used medicines or total 
medication and OH. 
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5.3.4 Orthostatic hypotension and pulse pressures 
Pulse pressure was significantly higher in the OH+ 
participants than in the OH– participants in a supine 
position, after one minute of standing and after three minutes 
of standing. After rising to a standing position, the decrease 
in pulse pressures was more pronounced in the OH+ 
participants than in the OH– participants.  
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6 Discussion 
6.1 STUDY POPULATION 
The Kuopio 75+ study and the GeMS study were both 
population-based studies with a random sample of elderly 
Finns aged 75 years or more, with wide inclusion criteria. 
More than 2 out of 3 of the participants were women. 
Previously, cardiovascular mortality has been higher in the 
area of East Finland, but during the past decades the 
differences in risk factors such as blood pressure levels have 
decreased, and serum cholesterol levels have become similar 
to those in West Finland (Nissinen et al. 1993). Therefore, the 
generalisability of the study results to the general elderly 
population in Finland is presumably good. Usually old 
patients differ from trial patients of any age due to their other 
comorbidities and multiple drug usage, which are often 
without exception exclusion criteria for entering clinical trials 
(Lye & Donnellan 2000). 
The participants in institutional care tended to be older 
and had poorer health status than the home-dwelling elderly. 
Due to missing data, the participants in institutions were 
excluded from work III and IV. In work II the intervention 
and control group were combined for the analysis. A 
Comprehensive Geriatric Assessment (CGA) of the subjects 
randomised into the intervention group was done yearly. The 
CGA was not specifically aimed at cardiovascular risk factors 
or serum lipids. There were no differences in the use of 
serum lipid modifying agents or cholesterol levels between 
the intervention and control groups during the study period, 
but there is a possibility to a different treatment between the 
intervention and control groups in 2006. 
High response rates are needed to ensure generalisability 
to a wider population. Compared with the other population-
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based studies among elderly persons, the response rates of 
86% (Kuopio 75+) and 78% (GeMS) can be considered rather 
good. The response rates of other studies among elderly 
persons have ranged between 78% and 96% (average 89%). A 
response rate of less than 70% has traditionally been 
considered poor and needs to be interpreted with caution 
(Jesson 2001).  
6.2 DESIGN OF THE STUDIES 
Both studies were prospective, population-based cohort 
studies. Work I, II and III were studies with a follow-up 
which allowed explanation of causes or consequences 
between variables. On the other hand, work IV was a cross-
sectional analysis, and this limits the present study results to 
proportions and associations. The main problem was in 
determining whether drug use preceded or followed the 
occurrence of the outcome (orthostatic hypotension) 
(Rothman & Greenland 1998, Rothman 2002).  
6.3 DEFINITIONS AND MEASUREMENTS OF THE STUDY 
VARIABLES 
The data were collected using different methods: clinical 
examinations, interviews and registry data were used. Drug 
use was measured both from databases and as a self-reported 
drug use. The use of a geriatrician to examine the 
participants’ overall physical and mental health increased the 
quality of the data collection and thus decreased 
misclassification of the study variables. Also, the study 
nurses were instructed and trained in data collection.  
Use of medicines 
Regularly and irregularly taken prescribed and non-
prescribed medicines were recorded. Compared with many 
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other studies, we also have data for OTC drugs. To ensure 
the reliability of the medication data, the medical records 
from the municipal health centre, home nursing service, local 
hospitals and the Kuopio University Hospital were also 
available. The reliability of the collection of medication data 
was also improved by asking the participants to bring their 
medicine containers and prescription forms with them to the 
interview, and medication information was also checked 
from the medical records and caregivers or family members, 
if needed. Cardiovascular medicines are typically used daily 
for a long period. Especially in cross-sectional studies 
regularly used medications are likely to be recorded more 
reliably than irregularly used (Ryynänen 1993). 
Blood pressure 
The main sources of systematic error in blood pressure 
measurement in hypertension are differences in the devices 
and differences in the measurement techniques of the 
observers (nurse/physicians). To avoid errors like inaccuracy 
of the device and the circumstances of measurement, blood 
pressure was measured twice after ten minutes of rest in a 
sitting position by a trained nurse using a calibrated mercury 
column sphygmomanometer according to the national 
guidelines (Käypä hoito: Kohonnut verenpaine 2009, Beevers 
et al. 2001).  
Orthostatic hypotension 
The prevalence of orthostatic hypotension was based on one 
measurement. Therefore, the observed results may be 
weakened by misclassification of the main exposure 
variables. In clinical practice, the skills and knowledge of 
nurses are often inadequate for diagnosing OH in elderly 
patients (Vloet et al. 2002). In our study, the study nurses 
were instructed and trained to measure blood pressures 
accurately. The blood pressure recordings were made after 10 
minutes’ rest, but the time of day for measuring blood 
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pressure, meals and daily activities differed between persons, 
which may have influenced our results. 
Cholesterol levels 
All the serum total cholesterol assays were analysed in the 
Kuopio University Hospital laboratory using standard 
enzymatic techniques according to the national guidelines 
(Käypä hoito: Dyslipidemiat 2009). Cholesterol was 
measured only once each time, so the observed results may 
be weakened by misclassification of the main exposure 
variables. Serum total cholesterol was measured once after 12 
hours of fasting and analysed in the Kuopio University 
Hospital to guarantee the accuracy of the analysis. The 
technique employed had to detect small changes and 
differences in cholesterol levels. In work II, the persons were 
categorised as having changes in their cholesterol levels 
during the study period only if the difference between levels 
was greater than +/- 0.2 mmol/l for total cholesterol and LDL 
cholesterol and +/- 0.1 mmol/l for HDL cholesterol. 
 
Concomitant diseases 
We used the National Social Insurance Institution Special 
Refund Registers for 2003 and 2005 to define concomitant 
diseases in work II to ensure equality between the 
intervention and control groups. We classified a participant 
as having a disease if the participant was entitled to special 
refunds for the medication costs of that disease before the 
respective examination. The non-risk subgroup with 
cardiovascular outcomes included non-smoking elderly 
persons without special refunds for diabetes, coronary artery 
disease and hypertension medication costs. To increase the 
reliability of the classification into the non-risk subgroup, the 
patient records were reviewed from the hospital and health 
centre for any diagnosis of coronary artery disease, diabetes 
or hypertension (current/past).  
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6.4 Discussion of the results 
6.4.1 Use of cardiovascular medicines 
In the Kuopio 75+ study the proportion of elderly persons 
regularly using cardiovascular medicines increased from 80% 
to 87%, and their common use was comparable to the 
findings of other studies (Wills et al. 1996, Barat et al. 2000, 
Strandberg et al. 2001). Still, their use in our study was more 
common than in some earlier studies (Nissinen et al. 1989, 
Lloyd-Jones et al. 2005). Concomitant use of at least three 
cardiovascular medicines increased, so cardiovascular 
medicines might be one reason why total medication use 
increases with advancing age. Today elderly men and 
women are treated more actively than before, also for 
cardiovascular diseases. Elderly persons living in institutions 
used significantly more loop diuretics than home-dwelling 
elderly persons, and their use increased more than among the 
home-dwelling survivors. Loop diuretics are often necessary 
in the treatment of heart failure in elderly persons, but in 
addition to loop diuretics, the guidelines have also 
recommended using ACE inhibitors and beta blocking agents 
in the treatment of heart failure (Gambassi et al. 1998).  
The increased use of cardiovascular medicines reflects the 
high prevalence of cardiovascular diseases in older age, 
because the proportion of users increased even though 
preventive medicines like low-dose aspirin, warfarin and 
lipid modifying agents were not counted. In Finland, 
cardiovascular medicines were the third biggest group in 
terms of sales, and consumption increased by 8% in 2008, so 
the study subjects do not differ from the total population 
(Suomen lääketilasto 2008). Medicine users treated for 
cardiovascular diseases had a more than four times higher 
risk for polypharmacy than drug users in general (Bjerrum et 
al. 1998, Jyrkkä et al. 2006). Use of cardiovascular medications 
together with polypharmacy and age-impaired renal and 
hepatic function may increase the risk of adverse events that 
are not well defined among the elderly population. An 
67 
 
 
additional problem is physicians’ reluctance to discuss about 
possible adverse events with elderly patients. According to a 
recent study, physicians told about adverse events to less 
than half of men and one-third of women aged 75 year or 
older (Meriranta 2009). 
6.4.2 Cholesterol values and use of serum lipid modifying 
agents 
In 1998 only 7% of all elderly persons used serum lipid 
modifying agents, while in 2004  in the GeMS study, one-
third of the study population used cholesterol-lowering 
medicines during the two-year follow-up period. Our results 
are consistent with some previous studies that have reported 
increased use of cholesterol-lowering medicines among 
elderly persons (Raymond et al. 2007, Korhonen et al. 2008b). 
In 20042006, the use of serum lipid modifying agents 
increased among those aged 7584 years, but not among 
those aged 85 years or more. Among those with three or 
more risk factors, two-thirds used these drugs. It seems that 
treatment practices have changed towards more active 
secondary prevention in elderly persons. In our study, the 
prevalence of serum lipid modifying agent use in patients 
with established coronary heart disease was much higher 
than the estimates in a previous study (Primatesta & Poulter 
2006). On the other hand, 14% of the elderly persons without 
traditional risk factors of cardiovascular outcomes used lipid 
modifying agents in 2006. Most of the data on drugs have 
been obtained from middle-aged persons, but it is estimated 
that the use of serum lipid modifying agents together with 
polypharmacy and impaired renal and hepatic function and 
certain concomitant medications may increase the risk of 
clinically important adverse events (Routledge et al. 2004). In 
addition, the incidence of muscle pain and other less severe 
adverse events is not well defined among the elderly 
population.  
The cholesterol levels improved during the follow-up 
period, with men having better outcomes than women both 
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among those not using any medicines and those using 
cholesterol-lowering medicines. Also those with CAD and 
several risk factors had lower cholesterol levels. Although 
women had higher cholesterol levels in both years, the use of 
cholesterol-lowering medicines was higher among men, like 
in many other studies (Daly et al. 2006, Enriquez et al. 2008). 
This may indicate that symptoms of coronary artery disease 
in older female patients are not recognised. 
A high S-TC level was not associated with an increased 
risk of all-cause mortality during the six-year follow-up. The 
inverse association remained clear and significant when 
adjusted for co-morbid diseases. In fact, high cholesterol 
levels in elderly persons do not seem to be a risk factor of 
mortality (Schatz et al. 2001, Schupf et al. 2005). The overall 
predictive power of cholesterol on mortality seems to decline 
with age (Menotti et al. 1998). Our results support previous 
reports on increased risk of death associated with low total 
cholesterol (Kronmal et al. 1993, Corti et al. 1997Weverling-
Rijnsburger et al. 1997, Song, Sung & Kim 2000, Schatz et al. 
2001, Brescianini et al. 2003, Casiglia et al. 2003, Schupf et al. 
2005, Tikhonoff et al. 2005, Spada et al. 2007). One 
explanation might be that all our participants were 75 years 
or older, with a mean of over 81 years at the baseline, a value 
higher than in many other studies (Corti et al. 1997, Casiglia 
et al. 2003, Brescianini et al. 2003, Schupf et al. 2005). 
Therefore, it is possible that our participants were less 
susceptible to diseases associated with high cholesterol than 
were those who died before the age of 75, either as a result of 
a lack of additional risk factors (smoking, diabetes, 
hypertension) or due to some undefined protective factors. 
The difference between age groups was seen in a Finnish 
study on subjects without coronary heart disease, where an 
increase in total cholesterol increased all-cause mortality in 
men aged 55 to 64, but not in men aged 65 to 74 (Pekkala 
1994). Unfortunately, only 30 elderly of those examined in 
1998 used serum lipid modifying agents. Due to the small 
number, those elderly treated with statins were excluded 
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from the analysis. Therefore, it is not possible to make any 
conclusions about the benefits and harms of lipid lowering 
treatment of the elderly in this population. The effect of total 
cholesterol level on mortality may be different in those using 
lipid lowering medication. On the other hand, our study 
results are significant due to their wide generalisability. In 
most clinical trials elderly women are underrepresented 
compared with men (Lewis et al. 1998, Hunt et al. 2001, 
Ridker et al. 2008).  
6.4.3 Orthostatic hypotension 
Systolic blood pressure dropped in two-thirds of the home-
dwelling elderly, and every third had orthostatic 
hypotension. This figure was higher than in many previous 
studies (Rutan et al. 1992, Masaki et al. 1998, Atli & Keven 
2006). OH and low blood pressure have been found to be 
associated with dizziness and an increased risk of falling, and 
too little attention has been paid to a drop in blood pressure 
too small to fulfil the criteria of orthostatic reaction (Rutan et 
al. 1992, Kario et al. 2001, Vloet et al. 2005). In frail elderly 
persons with low blood pressure, even a small drop in blood 
pressure can be a risk factor for falling. Previous studies have 
reported an increase in the prevalence of orthostatic 
hypotension with advancing age (Rutan et al. 1992, Masaki et 
al. 1998). That trend was not very obvious in our study 
population aged 75 or older. However, our population was 
older (mean age 81 years) than many of those previously 
reported, and they had multiple co-morbidities and 
medications. 
We found that a high number of regularly used medicines 
is associated with orthostatic hypotension. Poon et al found a 
relationship between OH and potentially causative 
medication (Poon & Braun 2005). In old individuals it is often 
impossible to determine whether OH is caused by medicines 
or the underlying diseases or both. In addition, our study 
was a cross-sectional study and this limits the conclusions. 
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The OH-positive participants showed an increase in heart 
rate slightly more often than the OH-negative persons, while 
a minority of the OH-negative persons maintained their 
blood pressure by increasing their heart rate. This might 
indicate that reflex tachycardia is secondary in preventing an 
orthostatic reaction even in elderly persons. In the present 
study, pulse pressure in a supine position was higher in the 
OH-positive than in the OH- negative subjects. This can be 
explained by the fact that an increased resting pulse pressure 
indicates stiffness of the major arteries. Still, after rising to a 
standing position the decrease in pulse pressure was also 
more pronounced in the OH-positive than in the OH-
negative persons. Increased pulse pressure has been 
associated with a risk of major cardiovascular complications 
and mortality (Blacher et al. 2000). However, mean pressure 
is not the only factor resulting in a high cardiovascular risk in 
old patients.  
OH in elderly persons was independent of blood pressure 
in the sitting position. In our study diastolic OH after one 
minute of standing was found to be more prevalent in 
persons with low blood pressure in a sitting position. In the 
study by Luukinen et al diastolic OH after one minute 
predicted cardiovascular mortality in old persons (Luukinen 
et al. 1999). In addition, a diastolic blood pressure drop after 
one minute of standing, even when it is small enough not to 
fulfil the criteria of orthostatic hypotension, identifies elderly 
persons with a high risk for myocardial infarction (Luukinen 
et al. 2004). This might be due to the load the heart is exposed 
to upon rising up, and it may provoke coronary insufficiency 
and a decrease in stroke volume in a frail elderly person.  
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7 Conclusions 
This doctoral thesis examined the use of cardiovascular 
medications in an elderly population. In addition, a number 
of associations and outcomes with used medications and 
orthostatic hypotension and cholesterol levels were studied. 
The following conclusions can be drawn: 
1. The use of cardiovascular medicines is common among 
elderly persons. The proportion of users increases with age 
and over time. 
2. The trend in current statin use seems to be moving 
towards more extensive use among elderly persons. Use of 
serum lipid modifying agents is targeted more at secondary 
prevention.  
3. A low serum total cholesterol level is associated with an 
increased risk of all-cause mortality among elderly who did 
not use serum lipid modifying medication. The inverse 
association remains clear and significant when adjusted for 
co-morbid diseases. 
4. Orthostatic hypotension and drops in blood pressure 
seem to be more common among home-dwelling elderly 
persons than has previously been reported. The more 
medicines are in regular use, the more common is orthostatic 
hypotension among (frail) elderly persons.   
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8 Implications for research 
and practice 
Concomitant use of cardiovascular medicines is in 
accordance with recent treatment guidelines. However, the 
prevalence of using several cardiovascular drugs 
concomitantly suggests that there is a need to assess the 
outcomes of treatment more comprehensively than before. 
Today we do not have any special treatment guidelines for 
the care of elderly persons. Appropriate use of cardiovascular 
drugs in the elderly requires knowledge of age-related 
physiological changes, the effects of concomitant diseases 
that alter the pharmacokinetic and pharmacodynamic effects 
of cardiovascular drugs, and drug– drug interactions. In 
order to create specific guidelines for treatment among the 
elderly population, we need more clinical trials in the use of 
cardiovascular medications in the elderly population aged 75 
years or more. 
The study results also suggest the need to test orthostatic 
hypotension in patients aged 75 years or older regardless of 
their blood pressure levels in a sitting position. In addition, 
clinicians should assess medication in persons with 
orthostatic hypotension to prevent risks of falling and 
cardiovascular hazards. Medication monitoring focused on 
elderly patients and cardiovascular medication might 
optimise treatment and improve the quality of care for a large 
proportion of elderly persons.  
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Cardiovascular diseases are 
responsible for one-third of global 
deaths and during recent years 
cardiovascular medicines have been 
the most commonly used medication 
among elderly persons. The present 
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use with a special emphasis on 
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was based on Kuopio 75+ study and 
GeMS study. 
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